A Compassionate Use (CU) Program of Odronextamab
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05619367 |
Expanded Access Status :
Available
First Posted : November 16, 2022
Last Update Posted : July 10, 2023
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Diffuse Large B-Cell Lymphoma (DLBCL) B-Cell Non-Hodgkin Lymphoma (NHL) High-Grade B-Cell Lymphoma (HGBCL) | Drug: Odronextamab |
Study Type : | Expanded Access |
Expanded Access Type : | Individual Patients |
See clinical trials of the intervention/treatment in this expanded access record. |
- Drug: Odronextamab
Other Name: REGN1979
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05619367
Contact: Requests for compassionate use must be initiated by a treating physician Physicians should contact | 844-734-6643 | CompassionateUseRequests@regeneron.com |
Responsible Party: | Regeneron Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT05619367 |
Other Study ID Numbers: |
R1979-Odronextamab |
First Posted: | November 16, 2022 Key Record Dates |
Last Update Posted: | July 10, 2023 |
Last Verified: | July 2023 |
Lymphoma Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type |
Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |